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compared with PCV7 and PCV13. At price parity, PHiD-CV is cost-saving to PCV7 
and PCV13 in Taiwan.
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OBJECTIVES: Antibiotics have made a signiﬁ cant contribution to improving patient 
health, but policy makers and health care payers are concerned about the costs of 
antibiotics in addition to their effectiveness. This study aims to assess the value of 
antibiotics by examining published incremental cost-utility ratios of antibiotics. 
METHODS: Evidence was derived from cost-utility analyses of antibiotics included 
in the Tufts-New England Center Cost-Effectiveness Analysis Registry through Sep-
tember 2009. For each cost-utility analysis, the following variables were examined: 
publication year, target population, intervention type, country of patient sample, 
disease classiﬁ cation, prevention stage, funding source, study perspective, discounting, 
sensitivity analysis, incremental cost-utility ratio, and methodological quality. Evi-
dence of the value of antibiotics was summarized by calculating median incremental 
cost-utility ratios and frequency distributions. Associations between incremental cost-
utility ratios on the one hand and the prevention stage, study perspective and meth-
odological quality were examined by means of the Mann-Whitney U-test for ordinal 
variables. RESULTS: The analysis included 85 incremental cost-utility ratios from 23 
cost-utility analyses. The ﬁ ndings showed that 38.8% of incremental cost-utility ratios 
related to dominant antibiotics; 45.9% referred to antibiotics that improved effective-
ness, but also increased costs; and 15.3% related to dominated antibiotics. The median 
ratio was c748 per quality-adjusted life-year. Using threshold values of c20,000 per 
quality-adjusted life-year and c50,000 per quality-adjusted life-year, the probability 
that an antibiotic provides value for money was 64% and 67%, respectively. No 
statistically signiﬁ cant association was observed between incremental cost-utility ratios 
and the prevention stage (p = 0.119), study perspective (p = 0.285) or methodological 
quality (p = 0.146). CONCLUSIONS: The current evidence base suggests that the 
majority of antibiotics provide value for money.
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OBJECTIVES: Prevalence of hepatitis C virus infection is approximately 2.2–3.0% 
worldwide (130–170 million people). a persistent infection develops in up to 85% of 
these patients, leading to chronic hepatitis C (CHC), a condition associated with 
serious liver-related complications. We aimed to perform an economic evaluation of 
peginterferon alpha-2a (PEG-IFN alpha-2a) plus ribavirin (RBV). METHODS: We 
developed a Markov model with 40 annual cycles to project cumulative cost and 
quality-adjusted life-years (QALY) for two identical cohorts of patients aged 40 years. 
One cohort received PEG-IFN alpha-2a 180 mcg per week plus daily doses of 
1200 mg of RBV during 48 weeks for genotype 1/4 or 24 weeks for genotype 2/3. 
The other cohort did not receive any antiviral treatment. The analysis was performed 
under the perspective of national public health care system. Only direct medical costs 
were accounted for; these included acquisition cost of antiviral drugs and medical 
attention for health states incorporated into the model. Costs (expressed in 2010 
Euros) and QALY were discounted at an annual rate of 5%. Transition probabilities 
and utility scores were gathered from published literature and cost data was based on 
local sources and experts’ opinion. RESULTS: Average discounted costs were esti-
mated at c15,626 for PEG-IFN alpha-2a plus RBV and at c17,350 when no antiviral 
treatment is given to CHC patients, leading to overall savings of c1724 per patient. 
Without antiviral treatment, 9.9 QALY per patient are expected. There is a gain of 
2.2 QALY for patients who are treated. Results are robust to variations in model 
parameters. PEG-IFN alpha-2a plus RBV was both more effective and less costly than 
no treatment in more than half of the simulations performed in a probabilistic sensitiv-
ity analysis. CONCLUSIONS: PEG-IFN alpha-2a plus RBV is a dominant strategy 
compared to given no antiviral treatment to CHC patients in Mexico.
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OBJECTIVES: Prevalence of hepatitis C virus infection is approximately 2.2–3.0% 
worldwide (130–170 million people). A persistent infection develops in up to 85% of 
these patients, leading to chronic hepatitis C (CHC), a condition associated with 
serious liver-related complications. Current standard of treatment includes Peginter-
feron (PEG-IFN) alpha plus ribavirin (RBV). We aimed to compare two different 
options of PEG-IFN alpha. METHODS: We developed a Markov model with 40 
annual cycles to project cumulative cost and quality-adjusted life-years (QALY) for 
two identical cohorts of moderate CHC patients without cirrhosis aged 40 years. One 
cohort received PEG-IFN alpha-2a 180 mcg per week and the other received PEG-IFN 
alpha-2b 1.5 mcg/Kg weekly, both combined with daily doses of 1,200 mg of RBV 
during 48 weeks for genotype 1/4 or 24 weeks for genotype 2/3. The analysis was 
performed under the perspective of national public health care system. Only direct 
medical costs were accounted for; these included acquisition cost of antiviral drugs 
and medical attention for health states incorporated into the model. Costs (expressed 
in 2010 Euros) and QALY were discounted at an annual rate of 5%. Transition 
probabilities and utility scores were gathered from published literature and cost data 
was based on local sources and experts’ opinion. RESULTS: Average discounted costs 
were estimated at c16,854 for PEG-IFN alpha-2a plus RBV and at c18,247 for 
PEG-IFN alpha-2b plus RBV, leading to overall savings of c1,393 per patient when 
PEG-IFN alpha-2a is used. Discounted QALY were 12.29 for PEG-IFN alpha-2a and 
12.17 for PEG-IFN alpha-2b. Results are robust to variations in model parameters. 
CONCLUSIONS: PEG-IFN alpha-2a plus RBV is a dominant strategy compared to 
given PEG-IFN alpha-2b treatment to CHC patients in Mexico.
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OBJECTIVES: To investigated the most important factors responsible for the large 
differences in previously estimated cost-effectiveness ratios and to update the cost-
effectiveness of rotavirus vaccination in the The Netherlands applying assumptions 
resulting from 2 consensus meetings with national and international experts in the 
ﬁ eld, from academia, clinical environments, industry and health policy. METHODS: 
We constructed a decision analytic model to compare the expected net costs and health 
beneﬁ ts over a period of 5 years in two hypothetical cohorts of 180,000 children 
(approximating the Dutch birth cohort), one being vaccinated and one unvaccinated. 
The base-case analysis reﬂ ected the most likely—but also overall conservative—esti-
mate of cost-effectiveness from the societal perspective. Robustness of the base-case 
result was investigated in sensitivity and scenario analyses. RESULTS: In the base-case 
analysis, it was estimated that approximately 59,495 RVGE cases would occur, result-
ing in 11,453 GP visits and 3,238 hospitalizations. With vaccination, approximately 
34,000 cases of RVGE cases are averted corresponding to a total QALY gain of 167. 
Assuming a total cost of vaccination of c75, vaccination would result in cost-effec-
tiveness of c30,540 per QALY gained (c152 per case averted). Results were sensitive 
to the number of deaths due to RVGE, inclusion of potential herd protection, inclusion 
of QALY decrements of care givers, further potential tender price reduction and the 
exact discount rate used. CONCLUSIONS: Our economic analysis indicates that a 
potential national immunization programme against rotavirus can be considered cost-
effective if applying a threshold of c50,000 per QALY for the The Netherlands.
PIN52
AN ECONOMIC EVALUATION OF RALTEGRAVIR FOR THE TREATMENT 
OF ANTIRETROVIRAL-NAIVE HIV-1 INFECTED PATIENTS IN HUNGARY
Erdesz D1, Nagy L1, Brandtmuller A1, Kiss Z1, Chaudhary MA2, Kumar RN3, Elbasha EH2
1MSD Hungary Ltd., Budapest, Hungary; 2Merck Research Laboratories, North Wales, PA, 
USA; 3Merck & Co., Inc., Whitehouse Station, NJ, USA
OBJECTIVES: Raltegravir (Merck & Co., Inc.) is an inhibitor of HIV type 1 (HIV-1) 
integrase, and is the ﬁ rst drug in a new class of therapy known as the integrase inhibi-
tors. Raltegravir has already shown to be cost-effective in HIV treatment experienced 
patients in Hungary. The objective of the current study is to assess if the ﬁ rst line use 
of raltegravir is cost-effective compared to its use in rescue therapy from the Hungarian 
public payer perspective. METHODS: First line use of raltegravir was evaluated versus 
a protease inhibitor (PI) using a Markov model. Raltegravir was also included as a 
3rd line therapy within the model arm that initiates on a PI. The Markov process 
comprised a three stage continuous-time model representing successive HIV therapies 
over a patient’s life-time. Patients moved between 18 health states—based on CD4 
and HIV RNA levels. Patients progressed to the next stage after they either failed 
current therapy or discontinued for toxicity reasons. At any time, patients could 
develop acquired immunodeﬁ ciency syndrome (AIDS), suffer from a coronary heart 
disease (CHD) event and/or experience other adverse events. Mortality was also 
captured in the model. RESULTS: The incremental cost-effectiveness ratio (ICER) for 
initiating therapy with raltegravir versus using it as a rescue therapy was 4,075 million 
HUF per quality adjusted life-year gained (QALY), equivalent to $16,830/QALY. The 
model predicted lower cumulative incidence of CHD in the raltegravir arm versus the 
PI arm. (15.1% versus 16.1%). The model predicted that patients initiating on ralte-
gravir therapy have longer life expectancy than patients starting with PI treatment 
over a 50-year time horizon (18.74 versus 17.17 years). CONCLUSIONS: Our long 
term economic model suggests that it is cost-effective to use raltegravir early in HIV 
therapy versus in patients who have experienced multiple failures.
